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1. Introduction 
Kidney transplantation evolved as the treatment of choice for end-stage renal disease. 
Accumulated expertise and experience along with refined surgical techniques resulted in 
excellent patient and graft survival. Despite the improvements in surgical techniques 
vascular complications consists a significant and sometimes life-threatening problem that 
occurs in 10-20% of patients. Vascular complication can be divided in general in three main 
categories. Graft renal artery thrombosis and stenosis, graft renal vein thrombosis and 
stenosis and arterial injury.  
2. Transplant renal artery stenosis  
Transplant renal artery stenosis (TRAS) is a very common vascular complication following 
kidney transplantations. It is reported in a wide range of frequency occurring in 3-12% of 
patients (in some reports even up to 20% depending on the awareness and the available 
imaging means especially MDCT-angiography) (Akbar 2005, Sebastia, 2001)]. It is very 
difficult to have the definitive true incidence of TRAS by looking at the literature and this 
discrepancy is due to the different definitions, the surgeon’s experience and technical skills 
in avoiding or preventing the TRAS and different peri-operative management. If we try to 
classify all arterial stenosis in kidney transplantation, we could divide it into two main 
categories; TRAS and proximal or pseudo-TRAS. TRAS can be categorised by the level of 
stenoses and this includes anastomotic stenoses, stenoses of the proper transplant renal 
artery and finally segmental renal artery stenoses. Proximal-TRAS refers to pre-existing or 
developing atherosclerotic inflow stenoses in the native iliac arteries of the transplant 
recipient. The incidence of proximal-TRAS has been reported to be 0%-2.4% and may 
become more prevalent with increasing age. Predisposing factors for transplant renal artery 
stenosis, are cadaveric transplant, end-to-end anastomosis, surgical clamp injury, intimal 
dissection, and inadequate suturing technique, long or kinking artery, prolonged cold 
ischemia time, acute cellular rejection, and cytomegalovirus (CMV) infection (Audard, 
2006).  
Patients with TRAS in the immediate post-transplant period, present oliguria or anuria and 
are dialysis dependent. After the first week, patients with TRAS usually present with severe 
renovascular hypertension. Even though severe renovascular hypertension could be 
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attributed to TRAS we should always keep in mind and all other causes like chronic 
rejection, steroid use, cyclosporine toxicity, recurrent glomerulonephritis and disease of 
native kidneys (Mangray, 2011, Tutone, 2005). If TRAS is not managed properly in due time, 
it could lead to renal dysfunction and graft deterioration. Non-invasive imaging is 
mandatory in the immediate post-transplant period to evaluate for possible transplant renal 
artery stenosis. Doppler ultrasound should be the initial diagnostic modality used because 
of its ability to reveal the location, length, and gross appearance of a stenosis. In addition, it 
is widely available, cost-effective, and does not use ionizing radiation and the nature of the 
transplanted renal arteries makes Doppler ultrasound an ideal screening modality (Baxter, 
1995, Irshad, 2008, 2009). Whilst Doppler ultrasound is ideal in recognizing a possible lesion, 
categorisation and better characterisation of TRAS would be using magnetic resonance 
angiography with or without contrast medium (especially gadolinium-enhanced), MDCT-
angiography, Radionuclide imaging that includes the administration of an angiotensin-
converting enzyme inhibitor (captopril scan) shows findings similar to those of renovascular 
hypertension in native kidneys (Sebastia, 2001). Catheter-based angiography is the gold 
standard technique for diagnosing TRAS. The use of low- or iso-osmolar contrast material is 
recommended to reduce the risk of contrast material–induced nephropathy. When renal 
insufficiency is present, carbon dioxide may be substituted for an iodinated contrast agent 
during preliminary angiography to minimize the use of iodinated agents.  
2.1 Definition and natural history 
Unfortunately there is no consensus definition of TRAS and it would be difficult to have 
one in the future. Usually there is the classic presentation with refractory hypertension, 
deteriorating renal function, and congestive cardiac failure secondary to fluid retention. It 
is very impressive that marked reversal of symptoms occurs when stenosis is successfully 
treated (Garovic, 2005, Mangray, 2011). The timeline of TRAS usually begins at 2 months 
to 2 years after transplantation and hypertension is due to activation of the renin-
angiotensin system (Basso, 2001, Mangray, 2011). Another important issue concerns 
asymptomatic normotensive patients with Doppler examination of at least 50% without 
evident graft dysfunction. The problem with those patients is the potential risk carrying 
from a procedure to treat a clinically insignificant TRAS in the short to medium term. It is 
unclear whether treating a non-clinically significant TRAS would have an impact in long 
term survival of renal grafts but since hypertension is an independent risk factor for long 
term renal graft survival, anything that could contribute to this direction would be 
beneficial. Close follow up of those patients, with significant expertise and experience of 
the transplant centre, along with availability of vascular interventional techniques is of 
paramount importance in decision making. Nevertheless, there are no reports of the long-
term safety of this line of management, and the natural history of a 50% TRAS is 
unknown, and that conservative treatment is safe provided that there is no deterioration 
of kidney function (Audard, 2006, Buturovic-Ponikvar, 2003). This may not be the case for 
other causes, such as intimal hyperplasia, and the indication for angiography is strong 
when graft deterioration is revealed in the absence of other causes of graft dysfunction or 
chronic allograft nephropathy (CAN). Increased awareness with follow up observation 
should be in case of a stenosis of 80% on ultrasound examination, even in cases without 
suspicion of a hemodynamically significant TRAS. Due to increased susceptibility to 
occlusion in the presence of dehydration or cardiovascular instability, and in this case 
intervention should be considered. 
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2.2 Pathophysiology 
Since Goldplatt et al published their study on the hypertensive role of partial reduced renal 
perfusion of the kidney back in 1934; there has been subsequent identification by various 
investigators of the role of the renin-angiotensin system, with renin being the hormone 
released in elevated blood levels from the ischemic kidney (Goldplatt, 1934). Angiotensin is 
being released enzymatically from angiotensinogen, and has various properties, including 
vasoconstriction, aldosterone secretion, renal sodium retention, and myocardium 
hypertrophy (Brewster, 2003). There is evidence that when there are two kidneys the above 
theory has been proven probably right, however it has been showed that this is not the case 
for the sole kidney or the transplanted kidney. Hypertension is also present but 
predominantly as a balance between volume regulation depending on salt and water 
retention and the renin-angiotensin dependent mechanism. It is the highly circulating 
volume and not the pressor effect from the renin-angiotensin system that is capable to keep 
a normal GFR rate with normal renin blood levels. In case that ACE inhibitors are prescribed 
there is a subsequent reduction in kidney perfusion and finally renal function deterioration. 
In patients with kidney transplantation, and in order to control hypertension, it is not 
uncommon to establish a diagnosis of TRAS, when an ACE inhibitor is introduced.   
2.3 Diagnosis 
Doppler ultrasonography is considered as the best screening test TRAS assessment. There 
are many advantages in the use of Doppler ultrasound as initial approach over other 
imaging methods, especially iodine contrast media. The fact that Doppler ultrasound is a 
noninvasive method, does not expose the recipient to the risk of iodine contrast 
examination, is widely and promptly available in all hospital settings makes it an excellent 
first choice for TRAS evaluation. The most significant limitation of the method, as in other 
conditions, is the fact that ultrasonography is operator dependent.  
Digital subtractive angiography (DSA), used to be the gold standard technique for 
establishing the diagnosis, but today tends to be replaced by MRI angiography and more 
recently Multi Detector CT-angiography. DSA is an invasive technique and potential 
complications are groin hematoma, renal artery dissection, thrombosis, perforation, and 
acute kidney injury caused by contrast-induced nephropathy. Doppler ultrasound can also 
be used to evaluate the hemodynamic changes due to TRAS. Doppler findings in TRAS 
include peak systolic velocity 2.0-2.5 m/s, low pulsatility index, and a parvus et tardus 
waveform with a systolic acceleration time of ≥ to 0.1 seconds (Snider, 1989, Irshad, 2009, 
Baxter, 1995). Snider et al compared Doppler ultrasonography with conventional 
angiography and showed 94% sensitivity and 87% specificity on US (Snider, 1989). A 
velocity ratio of the stenotic to pre-stenotic segments of greater than 2:1 is considered 
supportive of the diagnosis.  
Multidetectors helical CT gives accurate assessment of the site and degree of TRAS and 
provides accurate and valuable imaging, requires less volume of iodinated contrast medium 
than DSA (Sebastia, 2001). The nature of the vascular contrast medium may be of 
consideration, rather than the volume. Risk of contrast nephropathy is probably not related 
to the volume of contrast medium or the degree of renal failure (Birck, 2003, Pannu, 2004). 
Protection of the allograft with sufficient volume and N-acetylcysteine is recommended 
when intravenous contrast medium is injected, regardless of renal function and contrast 
volume. The alternative is to perform MRI with gadolinium, a non-iodinated contrast 
medium even though there have been reports of nephrogenic systemic sclerosis.  
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2.4 Treatment 
Treatment options for TRAS include both surgical and endoluminal options. Primary 
treatment for TRAS involves Percutaneous transluminal angioplasty (PTA) with or without 
stent placement (Audard, 2006, Bruno, 2004). The type of arterial anastomosis that is present 
is the deciding factor in determining the angiographic approach utilized. The technical 
success rate of PTA has been reported to be as high as 94%, with a clinical success rate of 
82% (Patel, 2001). Recurrent stenosis may occur in more than 10%, and allograft loss has 
been reported in up to 30% of cases (Fervenza, 1998).  There have been reports correlating 
TRAS with acute cellular rejection and that long term survival is significantly higher in non-
TRAS patients compared with the TRAS. Surgical revascularization is now considered 
rescue therapy and generally has been reserved for patients with disease unsuitable for PTA 
2.5 Endoluminal Interventions 
Since the introduction and the evolution of the endovascular interventions there has been a 
shift in TRAS treatment option with Percutaneous Transluminal Angioplasty (PTA) with or 
without the use of stent (Beecroft, 2004) being now the gold standard and the initial option 
of treatment. The method is considered very efficient especially in experienced hands and 
technical success has been reported to be greater than 90%. However when we consider the 
clinical impact that has on hypertension or improvement of allograft function, this is 
significantly lower.  
As we have already pointed out, the results in clinically insignificant TRAS can be evaluated 
only on the degree of the radiological success. PTA with or without stenting, is carrying a 
significant risk for the allograft and unless a significant pressure decrease exists across the 
TRAS, PTA should not be undertaken. Unfortunately there is no consensus as to the 
appropriate value of stenosis measurement beyond which intervention is warranted, and it 
would be very difficult to obtain one in the future since radiological success does not always 
results in clinical improvement. A cut off point proposed by Schoenberg et al (Schoenberg, 
2000), could be pressure decrease at least 10 mm Hg across the stenosis.  
The type of arterial anastomosis that is present is the deciding factor in determining the 
angiographic approach utilized. If there is an end-to-end anastomosis with the internal iliac 
artery, commonly done in living donor allografts, then a contralateral femoral approach is 
utilized to make access to the downward sloping artery as easy as possible. However, if 
there is an end-to-side anastomosis with the external iliac artery, then an ipsilateral femoral 
approach is preferred by some authors to access the cephalad sloping artery (Bruno, 2004).  
Results after PTA depend largely on the radiologists or vascular surgeons experience and 
expertise, and should have smooth cooperation with the transplant surgeons. Most of the 
complications relate to puncture site, but there could be also more severe complication like 
hemorrhage, rupture of transplant renal artery, iliac artery and loss of the allograft, in those 
case there could be a need for “salvage” operation. Evolution in endovascular technology, 
with newer pre-mounted stents, has minimised complications especially the life threatening 
ones and the risk for allograft loss. Rate of re-stenosis are reported to be 10% to 50% and 
depends on the primary cause of the stenosis, length of follow-up, and use of stents 
(Voiculescu A 2005). Even though there are several reports on the topic, there are limitations 
provided by the retrospective nature of those manuscripts and the limited number of 
patients. In a french study of 29 patients with TRAS treated with PTA, the technical success 
rate was 93.1%, and there was 27.5% re-stenosis (Audard, 2006). In other study from the US, 
TRAS was found in 26 (3.1%) renal allografts, and 17 were treated with PTA with a success 
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rate of 94%. Re-stenosis occurred in 12% of the patients [Patel NH 2001] In case of segmental 
branches, there is a lower success rate and the success rate is even lower for anastomotic 
strictures, and even though the incidence of stenosis is similar between end-to-side 
anastomosis to the external iliac artery and end-to-end anastomosis to the internal iliac 
artery, PTA in the latter situation is technically more difficult and results in a higher 
complication rate and more graft loss (Voiculescu, 2005). 
2.6 Surgical correction 
Surgical correction of TRAS is regarded as a difficult operation with graft loss rates 
exceeding 20% (Bruno, 2004). A couple of risks existing; to the recipient and to the allograft, 
the latter is not a contraindication to surgery, since severe TRAS could deteriorate the 
transplanted kidney, the patient proceeds to renal failure, and finally to end up in 
heamodialysis. Surgery is now considered as rescue therapy for cases unsuitable for PTA.  
In general indications for surgery include: TRAS caused by kinking, anastomotic strictures and 
complex atherosclerotic disease. There are several options to treat TRAS; mostly excision of the 
stenosis with direct anastomosis to the external iliac artery and grafting with saphenous vein, 
recipient internal iliac artery, and preserved ABO blood group compatible deceased donor 
artery. Reported surgical success rates range from 63% to 92%, with recurrence in 12% of 
patients (Roberts, 1989). A study comparing PTA vs. surgical repair of TRAS showed an 
immediate and long-term success rate of 92.1% and 81.5% and 69% and 40.5% for surgical 
repair and PTA respectively [Benoit G 1990]. Limitations of surgical procedure are access to 
the artery and most importantly the subsequent warm ischemia time. A warm ischemia of 60 
minutes might be tolerated by a kidney allograft that has been heparinised even though the 
risk for Acute Tubular Necrosis (ATN) and cortical necrosis is increased due to diminished 
blood flow. An alternative option even though rarely used, is back table reconstruction of a 
complex arterial problem and autotransplantation of the allograft.  
3. Transplant renal artery kinks and allograft torsion 
Positioning the allograft is sometimes tricky and the source of pitfalls in kidney 
transplantation and can result in allograft torsion. Allograft torsion can be an early or late 
complication. One of the main problems caused by improper positioning or torsion is the 
arterial kinking. Usually arterial kinks are formed due to long renal graft artery when there 
is a shift in the graft and/or pelvic contents that causes turn of the artery. Even though the 
differential diagnosis between TRAS and arterial kinking is often difficult to have, it is of 
paramount importance to identify an arterial narrowing due to a kink and not TRAS. 
Prompt diagnosis permits graft detorsion and possible salvage. The most suggestive 
imaging finding is a change in the axis of the transplanted kidney. CT and MR imaging can 
show changes in renal graft orientation and vascular pedicle kinking. Surgery remains the 
primary treatment for arterial kinks and only in cases where surgery is contraindicated or 
patients refuses surgery, we should proceed with endovascular treatment. TPA with or 
without stents, may increase the risk of arterial vasospasm and dissection and in addition, 
placing stents across kinks usually can be technically demanding. 
4. Thrombophilias 
The thrombophilias, also referred to as hypercoagulable states, comprise hereditary or 
acquired conditions that predispose individuals to thrombosis. It was the third factor of 
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Virchow’s triad that suggested that systemic alterations in the coagulability of blood, is a 
critical factor in thrombogenesis (Virchow, 1856). Thrombophilias are classified as 
congenital (inherited), acquired (secondary), or both (mixed) conditions (Schafer, 2007).  
Congenital hypercoagulable states are caused by inherited thrombotic disorders due to 
mutations in genes encoding plasma proteins involved in coagulation mechanisms. They 
can be broadly classified into two categories: 1) quantitative deficiencies or qualitative 
defects of the physiologic anticoagulants: antithrombin, protein C and protein S deficiency, 
and 2) increased levels or function of the coagulation factors: factor V Leiden, prothrombin 
gene mutation, elevated levels of specific coagulation factors (Schafer, 2003). Congenital 
abnormalities of anticoagulant or procoagulant proteins result in an increased risk for 
venous thromboembolism (VTE) as well as arterial thrombosis with the risk to be higher in 
cases with decreased levels of antithrombotic proteins than in those with increased levels of 
prothrombotic proteins. The overall incidence of venous thromboembolism (per 100 patient-
years) is found to be 1.07 for antithrombin deficiency, 0.54 for protein C deficiency, 0.50 for 
protein S deficiency, and 0.30 for activated protein C resistance or factor V Leiden 
(Bucciarelli, 1999). Half of the patients with inherited hypercoagulable state present with 
venous thromboembolism before the age of 45 years, particularly in the absence of well 
recognized risk factors, and often have a family history of thrombosis (Anderson, 2010). The 
secondary hypercoagulable states encompass a variety of heterogeneous disorders that have 
been associated with an increased risk of thrombotic complications (Schafer, 2003). Acquired 
hypercoagulable states include antiphospholipid antibody syndrome, cancer, heparin-
induced thrombocytopenia, pregnancy and estrogen therapy, and a prior history of venous 
thromboembolism. Acquired coagulation defects are particularly common in patients with 
endstage renal disease (Wagenknecht, 1999). The prevalence of antiphospholipid antibodies 
in patients awaiting renal transplantation is more than 10%, but the rate of clinical events is 
far less than the frequency of thrombophilic states. Hyperhomocysteinemia is the typical 
hypercoagulable state that occurs due to a combination of inherited and acquired factors. 
Elevated serum levels of homocysteine have been associated with an increased risk of 
arterial thrombosis (myocardial infarction, stroke, and peripheral arterial disease) and 
venous thromboembolism (Cattaneo, 1999). 
After renal transplantation the donor kidney endothelium is conditioned to exhibit a 
prothrombotic state as a consequence of reperfusion injury, tissue trauma, inflammation and 
expression of tissue factor, in addition to the recipient immune response (Key, 1992, Irish, 
1999). The combination of a conditioned endothelium and a genetic or acquired 
predisposition to a hypercoagulable state increase the risk of thrombosis. Factors specific for 
the renal transplant patients that have been suggested to contribute to this thrombotic risk 
include the use of calcineurin-inhibiting drugs, high levels of homocysteine, diabetic 
nephropathy, antiphospholipid syndrome, cytomegalovirus infection, and the presence of 
proteinuria or nephrotic syndrome (Kujovich, 2004). 
It has been proposed that inherited risk factors of venous thromboembolism, such as factor 
V-Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) 
C677T, might be associated with poorer survival rates of transplanted kidneys, attributed to 
the context of graft perfusion defects, venous thromboembolic complications, and acute 
graft loss by vascular rejection, possibly reflecting immunological injury upon the vascular 
wall exacerbated or induced by the prothrombotic state (Heidenreich, 2003, Wuthrich, 2001). 
Later study with larger number of patients, did not find a statistically significant association 
of polymorphisms factor V-Leiden G1691A and MTHFR C677T with renal graft survival 
Meyer, 2007). 
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Factor V-Leiden mutation or activated protein C resistance is the most common inherited 
thrombophilic disorder, found in 5% to 8% of the general population, in 20% of patients 
with a first venous thrombosis, and in up to 50% of patients with a personal or family 
history of recurrent thrombosis (Kujovich, 2004). In renal transplant recipients, factor V 
Leiden has been associated with a variety of complications after renal transplantation and a 
significantly higher incidence of venous thromboembolism which occurred in up to 39% of 
FVL carriers (Wuthrich, 2001, Irish, 1997). Also FVL carriers had 12-fold higher risk of an 
early graft perfusion defect (Wuthrich, 2001). A higher risk of vascular rejection was found 
in FVL carriers, which was linked to the presence of endotheliolitis or fibrinoid necrosis on 
histopathology of renal grafts lost within the first year after transplant (Ekberg, 2000).  
The reported prevalence of prothrombin gene heterozygous mutation in renal transplant 
recipients is 3.7%, similar to that in the general population. The mutation was associated 
with a nearly threefold increased risk of graft failure, which was attributable to arterial, 
venous, or microvascular thrombosis in the majority of carriers (Fischereder, 2001, Kujovich, 
2004).  
A polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene coding for an 
enzyme that degrades the endothelium toxic product homocysteine have been associated 
with ESRD (Girndt, 2007). This mutation occurs in 50% to 90% of chronic dialysis patients 
presenting with mild hyperhomocysteinemia and have been associated with cardiovascular 
disease and vascular access thrombosis in this population (Mallamaci, 2005, Mallamaci, 
2002). Additionally hyperhomocysteinemia can be acquired, such as in renal failure and in 
deficiencies of folate, vitamin B12, or vitamin B6.  Even though many studies found that 
hyperhomocysteinemia is an independent risk factor for both first and recurrent venous 
thromboembolism (den Heijer, 1996, Cattaneo, 1999) and that hyperhomocysteinemia is an 
independent risk factor for cardiovascular disease (Ducloux D et al 2000), the effect of 
hyperhomocysteinemia on the risk of graft thrombosis is unknown. Antiphospholipid 
syndrome is the most common acquired blood protein defect associated with either venous 
or arterial thrombosis or both (Koniari, 2010). Antiphospholipid antibodies (APLA) are 
found in approximately 10% of patients awaiting renal transplantation. Since only a fraction 
of patients with antiphospholipid antibodies experience thrombotic complications, the 
description of antiphospholipid antibody syndrome (APAS), defines by the presence of 
antiphospholipid antibodies and a clinical history of thrombosis. Antiphospholipid 
antibodies include not only the lupus anticoagulant (LA) and anticardiolipin antibodies 
(ACLAs) but also more recently recognized subgroups of antiphospholipid antibodies 
(antibodies against beta-2-glycoprotein-I [B-2-GP-I]) and antibodies to phosphatidylserine, 
phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, 
phosphatidylcholine, and anti-annexin-V (Bick, 2003). Patients with antiphospholipid 
antibodies in association with other autoimmune disease, most commonly lupus, are 
classified as having secondary antiphospholipid syndrome. Approximately 40% of patients 
with SLE have an antiphospholipid (anticardiolipin) antibody (lupus anticoagulant). The 
presence of antiphospholipid antibodies has been recognized as an important risk factor for 
early allograft failure (Wagenknecht, 1999. Patients with APAS are at high risk for 
renovascular thrombosis and renal allograft loss was reported to be universal in the absence 
of anticoagulation (Vaidya, 2000). Whereas, and despite the lack of anticoagulation, no 
allografts were lost to thrombosis, in patients with detectable anticardiolipin antibodies but 
no prior history of thrombosis. In a later report all patients with antiphospholipid antibodies 
were successfully transplanted using postoperative anticoagulation (Morrissey, 2002).  
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Other prothrombotic changes that have been reported in renal transplant recipients include 
decreases in antithrombin, protein C and protein S levels, markedly elevated factor VIII 
levels and over-expression of plasminogen activator inhibitor-1 by donor epithelium 
(suggestive of impaired regional fibrinolysis) (Irish, 1999). 
In vitro data suggest that immunosuppressive drugs like cyclosporine and OKT3 may 
increase the risk of thrombosis but an independent clinical association with allograft 
thrombosis is unproven (Gruber, 1989, Abramowicz, 1992). Specifically, the prothrombotic 
effects of cyclosporine include activation of monocytes to express tissue factor, increased 
platelet aggregation, endothelial dysfunction and activation of the intrinsic coagulation 
pathway, impaired fibrinolysis and impaired activation of protein C (Carlsen, 1988, 
Fishman, 1991, Bombeli, 1996, Evans, 1997, Levi, 1992). 
Thrombotic complications after renal transplantation are usually catastrophic. Inherited and 
acquired hypercoagulable states have to be considered prior to kidney transplantation and 
proper prophylactic treatment initiated for the purpose to improve transplant outcome. 
Andrassy et al. provided specified screening recommendations for thrombophilia prior to 
kidney transplantation (Andrassy, 2004). A general screening for thrombophilia, to include 
factor V Leiden, prothrombin gene G20210A polymorphism, antithrombin III, protein C and 
S activity, antiphospholipid antibodies and lupus anticoagulant, should be performed in all 
children and adolescents because they have the highest risk for thrombotic complications. 
Adults only with history of thrombotic events should be thoroughly screened (recurrent 
AVC fistula thrombosis should be taken into account). When risk factors are absent, 
screening only for antiphospholipid antibodies and lupus anticoagulant is recommended. 
There is also no consensus on the optimal management of renal transplant patients with 
thrombophilic disorders. Treatment strategies to reduce thrombotic risk including heparin, 
warfarin, and aspirin have been evaluated in several reports. While inadequate 
anticoagulation may place the patient at risk for thrombosis, preemptive or intense 
perioperative anticoagulation can result in postoperative bleeding (Morrissey, 2002, 
Murashima, 2010, Friedman, 2001). Morissey et al. (Morrissey, 2002) recommended 
management approach for renal transplant patients with thrombophilia. Patients with 
diagnosis or suspected to have thrombophilia is suspected, the risk for thrombotic 
complications should be stratified as low, intermediate or high. In high risk are patients 
with inherited thrombotic disorder and history of at least two thrombotic episodes. For the 
high risk patients indefinite oral anticoagulation has been advocated. In intermediate risk 
are patients with a known inherited thrombotic disorder who are asymptomatic or have 
experienced a single thrombotic event. They should receive adequate prophylaxis in high-
risk situations such as surgery for a minimum of 6 months. For patients with no suspicion of 
thrombophilia, no anticoagulation or a short term postoperative anticoagulation may be 
given. 
5. Renal vein and artery thrombosis 
Renal transplantation is established as the preferred treatment for most cases of end-stage 
renal disease. Postoperative vascular complications include thrombosis of renal vein and 
artery, with a delay in the diagnosis and management of these complications leading to 
significant morbidity for the recipient, with a high risk of graft loss and mortality (Akbar, 
2005). It consists of a rare complication that often results in graft loss, with reported 
incidence ranging from 0.4% to 6% (Rouviere, 2002, Giustacchini, 2002). Bakir et al reported 
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that thrombosis represented 45% and 37% of renal allograft loss at 3 and 12 months (Bakir, 
1996). 
5.1 Renal vein thrombosis 
Renal vein thrombosis (RVT), although an unusual event, most often has graft loss as a 
result (Figure 1). The causes that may lead to this serious complication include compression 
due to hematomas or lymphoceles, angulation or kinking of the vein, anastomotic strictures, 
or an underlying state of deep venous thrombosis or hypercoaguability (Penny, 1994). RVT 
usually occurs suddenly and towards the end of the first week of an otherwise 
uncomplicated kidney transplantation. Specifically it occurs in the first 2 weeks post 
transplant, with 80% occurring in the first month and 93% within the first year (Kobayashi, 
2007). Clinical presentation is initiated by oliguria and hematuria with a tender swollen 
graft, which if ruptured, is accompanied by life-treatening bleeding (Kobayashi, 2007). 
 
 
 
 
Fig. 1. Specimen of renal allograft nephrectomy due to renal vein trhrombosis 
5.2 Renal artery thrombosis 
This uncommon complication which may occur most often as an early but also as a late 
event after kidney transplantation consists a devastating clinical condition leading 
frequently to graft loss. Renal artery thrombosis (RAT) onset most often follows a technical 
problem such as intimal dissection, kinking or torsion of the vessels. Risk factors include 
poor cardiac output, hyperacute rejection, unresponsive acute rejection, and a 
hypercoagulable state. It presents with a rapid onset of oliguria. In cases of segmental 
infarct, there can be lack of symptomatology or a presentation of renal dysfunction and 
increased blood pressure. When RAT occurs as a late event, it could be attributed to renal 
artery stricture or its manipulation post-operatively e.g. during angiography, or usually due 
to graft rejection.  
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5.3 Diagnosis 
An early clinical diagnosis is very important for both RVT and RAT, even during the 
morning ward round. Diagnosis of these complications is established by colour flow 
Doppler studies, demonstrating in RVT a swollen graft with a crescent of clot along the 
convex margin of the kidney. In this case it is essential that the patient is taken immediately 
to theatre. Under normal clinical conditions, the spectral Doppler renal arterial waveform 
shows high resistive index with reversal of diastolic flow. On the contrary, in RAT a lack of 
flow in the renal artery is demonstrated, with the presence of intraluminal filling defects. In 
RAT, diagnosis is set by Doppler studies or at time of surgical exploration, however by that 
time it is not possible for the graft to be saved due to the kidney’s low tolerance to warm 
ischemia (Rouviere, 2002).  
5.4 Treatment  
Following establishment of diagnosis for RVT, the treatment of choice is urgent 
thrombectomy. However graft salvage may not be possible, in which case graft 
nephrectomy is usually required. In case thrombectomy is applied early, within 1 hour 
following the event, graft salvage can be achieved. The increased risk of swelling, edema 
and also a possible rupture of the kidney graft in such a condition, makes urgent exploration 
essential. Systemic anticoagulants can be applied as treatment only in cases of partial vein 
thrombosis. 
The surgical treatment for renal graft thrombosis includes laparotomy, thrombectomy and 
ultimately a possible graft nephrectomy. Several authors describe endoluminal therapy 
for renal graft thrombosis; however the exact role of interventional radiologic treatment is 
not yet well-defined (Obed, 2008). The technique for percutaneous treatment involves 
placing the tip of a catheter within the thrombus, 1 cm distal to the surgical anastomosis, 
with infusion of a thrombolytic agent (Rouviere, 2002). Because transcatheter 
thrombolysis revascularizes arteries at a slower rate than surgical thrombectomy, patients 
with a heavy clot burden should be primarily offered surgical treatment (Hedegard, 2009). 
Transcatheter thrombolysis should be limited to low clot burden, segmental artery 
thrombosis, or high-risk surgical candidates. Additionally catheter-directed thrombolytics 
should be avoided in the first 2 weeks following kidney transplant due to the immature 
anastomotic suture line. On the other hand RAT can be determined as a terminal event, 
which can be averted only if poor graft function can be attributed to arterial inflow and in 
this case intervention should be immediate. By the time the diagnosis is set, the 
transplanted kidney is lost.  
5.5 Prevention 
Although in many cases of renal allograft vascular thrombosis, no cause can be identified, 
epidemiological studies have attempted to categorise risk factors as modifiable, including 
drugs and the surgical procedure among others, and nonmodifiable, including age, diabetes 
mellitus and vascular anomalies. Additionally studies have identified changes in 
coagulation or fibrinolysis promoting a more thrombotic state, as risk factors as well.  
Prevention may hold an important role in avoiding the formation of vascular thrombosis. 
This requires of course a combination of different measures such as avoiding prolonged cold 
and warm ischemia. Attention to precise surgical technique, use of preservation solution 
such as University of Wisconsin solution and an immediate and effective management of 
rejection, should all be outlined as important in the prevention strategy. 
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Additionally identification and management of thrombophilic states could act as a 
preventive measure against renal vascular thrombosis, with a possible need for routine 
screening and directed therapy to reduce the risk of thrombosis and graft loss, however no 
consensus for either strategy have been introduced. Previous reports indicate a possible 
laboratory investigation to potential recipients with a previous history or family history of 
thrombotic events, such as deep and superficial vein thromboses, pulmonary emboli, 
fistulas having been thrombosed or incidents of multiple occlusions of central venous 
dialysis catheters, as well as patients undergoing preemptive transplantation with a living 
donor kidney (Andrassy, 2004). 
The risk of thrombosis must be balanced against that of bleeding. For known thrombophilia 
and a history of clinical events, perioperative heparinization followed by long-term 
anticoagulation with warfarin has shown good results, including successful 
retransplantation. However since results of the few available, prospective randomized 
studies on heparin use in renal transplant patients, show conflicting conclusions, one 
understands that there is a great need for a preoperative classification of thrombotic and 
hemorrhagic risk among renal transplant candidates and for establishment of consensus 
guidelines. 
6. Extrarenal pseudoaneurysm 
Extrarenal arterial pseudoaneurysms in renal transplantation are rare, and their prevalence 
is less than 1% (Bracale, 2009). Extrarenal pseudoaneurysms are directly related to arterial 
anastomosis, percutaneous nephrostomy placement and infectious causes. It is usually 
asymptomatic and rarely can cause renal dysfunction or compression of adjacent structures 
(Bracale, 2009). When extrarenal pseudoaneurysms become large, there is a strong 
indication to be surgically removed to avoid spontaneous rupture and loss of the allograft 
(Figure 2).  
 
 
       
 
 
Fig. 2. External iliac artery pseudoaneurysm presented as a complication of renal vein 
thrombosis and allograph nephrectomy. The pseudoanurysm was formed at the stump of 
the arterial anastomosis due to inflammation. Preemptive treatment with double stent 
placement was successfully performed.  
www.intechopen.com
 Understanding the Complexities of Kidney Transplantation 558 
7. Arteriovenous fistula 
Arteriovenous fistula (AVF) is a well-recognized vascular complication of percutaneous 
biopsy. The reported incidence of AVF ranges between 0.5 and 16% (Martinez, 1998). An 
arteriovenous fistula (AVF) may be formed when both arterial and venous walls are 
punched by the biopsy needle. Mostly they are asymptomatic, rarely may cause persistent 
hematuria or recurrence of hematuria, hypertension and deterioration of renal function. 
Rarely, renal graft ischemia may be the result of steal phenomenon from a large AVF 
(Harrison, 1994, Matsell, 1992, Cruzado, 19990. Factors that may predispose to the 
development of arteriovenous fistula include early postransplant period, the presence of 
hypertension, sclerosis and interstitial fibrosis, the formation of intrarenal hematoma 
(Schwarz, 2008). About 70% of AVF cases resolve spontaneously within weeks or months 
(Matsell, 1992). 
Doppler sonography allowing noninvasive diagnosis of AVFs is the diagnostic 
examination of choice (Ozbek, 1995). Angiography is the reference standard as it confirms 
the presence of the AVF, accurately assesses its size and location, and permits 
endovascular treatment (Loffroy, 2008). On Doppler, the AVF shows a focal area of 
turbulent flow and a localized region of disorganized color that extends outside the 
normal vessels on color Doppler. In the area of AVF, the duplex US shows a very high 
velocity with low resistive index in the feeding artery with arterialization of the flow in 
the draining vein (Irshad, 2009). 
In most cases AVFs close spontaneously within a few months, but they warrant observation 
to exclude the need for therapeutic intervention. The likelihood of and time to spontaneous 
closure in renal allografts, and the optimal time for therapeutic intervention are not 
predictable (Loffroy, 2008). Treatment has been recommended when bleeding persists for 
more than 72 h, renal function deteriorates markedly, lesion enlarges and there is suspicion 
of steal phenomenon. Endovascular superselective embolization is the therapeutic 
procedure of choice, as loss of normal parenchyma is minimal, with success rate of 
approximately 88% with no significant loss of allograft function (Loffroy, 2008, Tarif, 2002). 
In the majority of cases, successful embolization can be achieved using coils or microcoils. 
Schwarz et al (Schwarz,2008) proposed a hemodynamic prognostic test to predict which 
AVF would probably profit from AVF coiling, by comparing Doppler sonographic resistive 
indices of the main renal artery and the non-AVF associated segmental arteries (Schwarz, 
2008). The resistive index of the main renal artery should be at least 0.05 less than that of the 
non-AVF-associated segmental renal arteries indicating under-perfusion of the rest renal 
parenchyma. 
8. Conclusions 
Renal transplantation is regarded as an optimal treatment for End-stage renal disease. 
Improvements in surgical techniques and advanced immunosuppressive drugs have 
resulted in remarkable survival of patients and renal grafts. However complications occur in 
both the immediate postoperative period and later. Awareness for early post-operative 
complications, like renal vein and artery thrombosis could save allografts and patients. 
Cardiovascular disease remains the most frequent cause of death and transplant loss after 
kidney transplantation, with hypertension present in vast majority of kidney transplant 
recipients and a risk factor for cardiovascular disease. Improvements in imagining 
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modalities and interventional techniques resulted in earlier identification and management 
of TRAS. It is of paramount importance for the transplant surgeon to keep in mind that early 
and late vascular complications after renal transplantation could be very challenging and 
potentially allograft and/or life threatening  
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